In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daniel Chancellor

Latest From Daniel Chancellor

European Investor Sentiment Rebounds On Cell And Gene Therapy

Investors at the Advanced Therapies Europe conference in London struck a bullish note on the state of the market and offered up advice for cell and gene developers from fundraising, platform development to manufacturing.

Gene Therapy Europe

Pandemic Windfall Upends Status Quo For Top-10 Best-Selling Drugs

This article reveals the top 10 pharmaceutical products by revenues in 2022 and discusses the major themes affecting the highest-grossing drugs and the companies behind their continued development.

Growth Sales & Earnings

Juicy Apples Come From Healthy Trees: Advice For Platform Developers

Speaking at BIO-Europe Spring, three leaders of platform life sciences companies offer advice on their scalable and lower risk business models that support innovation within partner biopharma companies.

Innovation Platform Technologies

How COVID-19 Disrupted The Clinical Trial Status Quo

As the world begins its transition into a post-pandemic existence, it becomes possible to look back on the past two years and begin to quantify the effects COVID-19 has brought. For the biopharmaceutical industry, clinical trials have been at the forefront.

Clinical Trials Coronavirus COVID-19

Fresh Recommendations For Rare Disease Trial Sponsors

Best practices to help sponsors design patient-centric studies, build trial awareness among important physician and health care professional groups, leverage advocacy groups to speed up patient recruitment, and ultimately gain a competitive edge in rare disease trial strategies.

Rare Diseases Research & Development

Editing The Future

Gene editing is positioning itself as the latest evolution of genetic therapies and is due for an inflection point in 2022 as a number of milestones will be reached.

Gene Therapy Innovation
See All
UsernamePublicRestriction

Register